Clinical TrialsThe EMPEROR Phase 3 study began dosing subjects, with approximately 130 subjects already identified in prescreening.
Financial PerformanceSTOK reported 2Q25 total revenue $14M vs. consensus $9M, showing better than expected revenue performance.
Regulatory ProgressManagement is talking about using Zorevunersin's Breakthrough Therapy Designation to have a multidisciplinary meeting with the FDA to discuss the data to date and explore expedited access of Zorevunersen for patients.